Cargando…
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
The introduction of monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP), or its receptor (CGRPr), revolutionized migraine management due to their high efficacy and few side effects. Data suggest that the CGRP may even be implicated in circadian rhythm, but studie...
Autores principales: | Pilati, Laura, Torrente, Angelo, Di Marco, Salvatore, Ferlisi, Salvatore, Notaro, Giulia, Romano, Marika, Alonge, Paolo, Vassallo, Lavinia, Ferraù, Ludovica, Autunno, Massimo, Grugno, Rosario, Camarda, Cecilia, Brighina, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219555/ https://www.ncbi.nlm.nih.gov/pubmed/37240692 http://dx.doi.org/10.3390/jcm12103585 |
Ejemplares similares
-
Sleep and Chronobiology as a Key to Understand Cluster Headache
por: Pilati, Laura, et al.
Publicado: (2023) -
OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment
por: Torrente, Angelo, et al.
Publicado: (2022) -
Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022) -
Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
por: Torrisi, Michele, et al.
Publicado: (2023) -
CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
por: De Luca, Ciro, et al.
Publicado: (2021)